Hugo Geerts on RIP: Serotonin Receptor 5-HT6 Antagonist

COMMENT Despite these setbacks, I would disagree that the 5-HT6 antagonist concept is dead. Although we don’t have the details, it is likely that the clinical trial design did not take into account the pharmacodynamic (PD) interactions of 5-HT6 antagonists with ...

Hugo Geerts on Merck Pulls Plug on Phase 2/3 BACE Inhibitor Trial

COMMENT The reported premature halt of the BACE inhibitor is a substantial setback, as the field desperately needs some success. Obviously, we need to scrutinize the clinical data in more detail before we can identify possible reasons. However, together with the ...

Hugo Geerts on Advisory Panel Grapples with Combination Therapy

COMMENT The proposal of combination trials, necessarily with amyloid-modulating interventions, is a substantial challenge, as discussed in an earlier post. Basically the different synthesis rates of Aβ1-40 and Aβ1-42 (Potter et al., 2013) and different ...

Hugo Geerts on In Familial AD, Aβ Production Up, Clearance Down

COMMENT The study by Potter et al. on amyloid-β production measured in vivo in PS1 and PS2 carriers is a clever combination of clinical observations, imaging studies, physics, and computational compartmental modeling to better quantify the "biology" of ...

Hugo Geerts on CONCERT Trial of Dimebon Falls Flat

COMMENT This is another unfortunate setback to the Alzheimer's community of researchers, clinicians, and patients. A possible way to turn this into something positive is to perform failure analysis, an approach used in many other industries (think aerospace) ...

Current Filters

  • TYPE: Comment x
  • Commentator: Geerts, Hugo x

Remove all filters

Filter By

  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From